FDA Launches New Organizational Performance Management System
FDA-TRACK monitors accountability, transparency; supports
Open Government Initiative
ROCKVILLE, Md., Aug. 31, 2010--The U.S. Food and Drug
Administration today launched an innovative performance management
system designed to advance the President’s commitment to
transparency, public participation, and collaboration in the work
of government.
The system, called FDA-TRACK, will monitor more than 100 FDA
program offices through data from key performance measures
established each year. That data will be gathered monthly, analyzed
and presented each quarter to FDA senior
leadership. Importantly, the public will be able to track this
data and the agency’s progress through the FDA-TRACK
website.
“FDA-TRACK will bring the operations of this historically
opaque Agency into the daylight and help us be even more responsive
as we work to protect the public health,” said FDA
Commissioner Margaret Hamburg, M.D.
FDA-TRACK is designed to be informative, encourage accountability
among the people who work at the FDA, and make that work more
transparent. It gives managers and employees a new way to measure
their effectiveness in meeting goals to protect the public health
and provides a way for the public to monitor agency
activities.
Adapted from several successful state and local performance
management models, FDA-TRACK hopes to set the standard for open
government at the federal level. The system monitors performance
indicators in four categories:
Common Measures – Agency-wide measures
applicable to each of more than 100 program offices and may
focus on the agency’s most recent priorities.
Example: Increase the total number of employees who are trained in
the Incident Command System, which helps the agency respond to
emergencies.
Key Center Director Measures –
Center-specific measures that are applicable to each Center and are
central to the Center’s priorities and strategic goals.
Example: Increase the FDA’s technical guidance by increasing
the number of technical publications drafted, which enables the
Center to better prepare industry and consumers.
Program Measures – Program office-specific
measures that are applicable to the office and reflect work
important to the public and to the FDA’s mission.
Example: Monitor the percentage of 510(k) decisions meeting the
90-day Medical Device User Fee Act goal during a specific time
period.
Key Projects – Program office-specific
projects that are applicable to the office and important to the
mission and objectives of the office. Performance for Key Projects
is measured through achievement of the stated milestones within the
project’s plan.
Example: The development of a new risk-based approach for
evaluating safety, effectiveness, and quality of new animal
drugs.
For more information:
Media Inquiries: Raymond Formanek Jr.,
301-796-4677, raymond.formanek@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
Posted: September 2010
